A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.


Updates from The Motley Fool

Latest updates on Keryx Biopharmaceuticals from Fool.com.  The Fool has written over 200 articles on Keryx Biopharmaceuticals.


Stock Performance

View Interactive KERX Charts
Sponsored by

Key Data Points

Primary metrics and data points about Keryx Biopharmaceuticals.
Current Price: $5.25
Prev Close: $5.02
Open: $5.00
Bid: $5.25
Ask: $5.34
Day's Range: $4.95 - $5.26
52wk Range: $3.32 - $7.80
Volume: 1,339,864
Avg Vol 1,442,136
Market Cap: $556M
P/E (ttm): -3.22
EPS (ttm): ($1.56)
Div & Yield: $0.00 (0.0%)

Company Rating

What our community thinks about Keryx Biopharmaceuticals.
CAPS Rating 2 out of 5
 
395 Outperform
63 Underperform
CAPS All Stars
 
44 Outperform
21 Underperform

How do you think Keryx Biopharmaceuticals will perform against the market?



You pick for Keryx Biopharmaceuticals is winning

Score: +97.74
Call: Outperform
Time Frame: Five Plus Years
Start Price: $18.24
Start Date: 3/29/2007
Gain/Loss: +$152.4%
S&P Gain/Loss: +$54.7%

Powered by Motley Fool CAPS


CEO Rating

The single most important factor in a company's success is the team that's leading the company.

Greg Madison, CEO

0% Approve

Based on 0 Ratings

Powered by Glassdoor

Business Summary

Industry, sector and description for Keryx Biopharmaceuticals.

A biopharmaceutical company focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer.

  • Exchange: NASDAQ
  • Sector: Healthcare
  • Industry: Drug Makers